ML-261

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameML-261
Drug Alias NameAutologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy (Moonlight Bio)DLL3 directed autologous Chimeric Antigen Receptor T cells Therapy (Moonlight Bio)ML261ML-261
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionDelta-like protein 3 modulatorsT lymphocyte replacements
TargetsDelta-like protein 3
Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMoonlight Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesMoonlight Bio Inc
Inactive CompaniesN/A
Active IndicationsGastroenteropancreatic neuroendocrine tumorProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A